RU2018111429A - Соли 1-(4-(2-((1-(3,4-дифторфенил)-1н-пиразол-3-ил)метокси)этил)пиперазин-1-ил)этанона - Google Patents
Соли 1-(4-(2-((1-(3,4-дифторфенил)-1н-пиразол-3-ил)метокси)этил)пиперазин-1-ил)этанона Download PDFInfo
- Publication number
- RU2018111429A RU2018111429A RU2018111429A RU2018111429A RU2018111429A RU 2018111429 A RU2018111429 A RU 2018111429A RU 2018111429 A RU2018111429 A RU 2018111429A RU 2018111429 A RU2018111429 A RU 2018111429A RU 2018111429 A RU2018111429 A RU 2018111429A
- Authority
- RU
- Russia
- Prior art keywords
- pain
- disease
- salt
- piperazin
- pyrazol
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title claims 16
- -1 2 - ((1- (3,4-DIFLUORPHENYL) -1H-PYRAZOL-3-YL) METHOXY) ETHYL Chemical class 0.000 title 1
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 8
- 208000004454 Hyperalgesia Diseases 0.000 claims 6
- 208000002193 Pain Diseases 0.000 claims 6
- COKUNRYWXTVUAH-UHFFFAOYSA-N 1-[4-[2-[[1-(3,4-difluorophenyl)pyrazol-3-yl]methoxy]ethyl]piperazin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCN1CCOCC1=NN(C=2C=C(F)C(F)=CC=2)C=C1 COKUNRYWXTVUAH-UHFFFAOYSA-N 0.000 claims 5
- 238000011282 treatment Methods 0.000 claims 5
- 208000035154 Hyperesthesia Diseases 0.000 claims 3
- 206010065390 Inflammatory pain Diseases 0.000 claims 3
- 206010053552 allodynia Diseases 0.000 claims 3
- 208000004296 neuralgia Diseases 0.000 claims 3
- 208000021722 neuropathic pain Diseases 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 2
- 238000011321 prophylaxis Methods 0.000 claims 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims 1
- YJZGDOPAALDWAT-UHFFFAOYSA-N 1-[4-[2-[[1-(3,4-difluorophenyl)pyrazol-3-yl]methoxy]ethyl]piperazin-1-yl]ethanone hydrochloride Chemical group Cl.CC(=O)N1CCN(CCOCc2ccn(n2)-c2ccc(F)c(F)c2)CC1 YJZGDOPAALDWAT-UHFFFAOYSA-N 0.000 claims 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 208000016192 Demyelinating disease Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 108090001030 Lipoproteins Proteins 0.000 claims 1
- 102000004895 Lipoproteins Human genes 0.000 claims 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims 1
- 229940025084 amphetamine Drugs 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229960003920 cocaine Drugs 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 229960004756 ethanol Drugs 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 239000011976 maleic acid Substances 0.000 claims 1
- 150000002688 maleic acid derivatives Chemical class 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 150000007522 mineralic acids Chemical class 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 229960002715 nicotine Drugs 0.000 claims 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 150000007524 organic acids Chemical class 0.000 claims 1
- 235000005985 organic acids Nutrition 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 108010085082 sigma receptors Proteins 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
- 150000003460 sulfonic acids Chemical class 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (12)
1. Кристаллическая соль 1-(4-(2-((1-(3,4-дифторфенил)-1Н-пиразол-3-ил)метокси)этил)пиперазин-1-ил)этанона.
2. Кристаллическая соль по п.1, где соль выбрана из группы, состоящей из неорганических кислот, сульфоновых кислот и органических кислот.
3. Кристаллическая соль 1-(4-(2-((1-(3,4-дифторфенил)-1Н-пиразол-3-ил)метокси)этил)пиперазин-1-ил)этанона по п.1, где указанная соль выбрана из гидрохлорида, малеата, фумарата, малоната, сукцината, оксалата и/или гидробромида.
4. Кристаллическая соль 1-(4-(2-((1-(3,4-дифторфенил)-1Н-пиразол-3-ил)метокси)этил)пиперазин-1-ил)этанона по п.1, где соль представляет собой гидрохлорид 1-(4-(2-((1-(3,4-дифторфенил)-1Н-пиразол-3-ил)метокси)этил)пиперазин-1-ил)этанона.
5. Кристаллическая соль 1-(4-(2-((1-(3,4-дифторфенил)-1Н-пиразол-3-ил)метокси)этил)пиперазин-1-ил)этанона по п.1, где соль представляет собой соль малеиновой кислоты и 1-(4-(2-((1-(3,4-дифторфенил)-1Н-пиразол-3-ил)метокси)этил)пиперазин-1-ил)этанона.
6. Фармацевтическая композиция, содержащая по меньшей мере кристаллическую соль по любому из пп. 1-5.
7. Кристаллическая соль по любому из пп. 1-5 для применения в качестве лекарственного средства.
8. Кристаллическая соль по любому из пп. 1-5 для применения при лечении и/или профилактики заболевания или состояния, опосредованного сигма-рецептором.
9. Кристаллическая соль по любому из пп. 1-5 для применения при лечении и/или профилактике заболевания, выбранного из группы, состоящей из диареи; липопротеиновых расстройств; мигрени; ожирения; артрита; гипертензии; аритмии; язвы; дефицита обучения, памяти и внимания; нарушений познавательной способности; нейродегенеративных заболеваний; демиелинизирующих заболеваний; зависимости от наркотиков и химических веществ, включая кокаин, амфетамин, этанол и никотин; поздней дискинезии; ишемического приступа; эпилепсии; инсульта; стресса; рака; психотических состояний, в частности, депрессии, тревоги или шизофрении; воспаления; или аутоиммунных заболеваний.
10. Кристаллическая соль по любому из пп. 1-5 для применения при лечении и/или профилактике заболевания, где заболевание представляет собой боль, предпочтительно невропатическую боль, воспалительную боль или другие состояния, связанные с болью, включая аллодинию и/или гипералгезию.
11. Гидрохлоридная соль по п.4 для применения при лечении и/или профилактике заболевания, где заболевание представляет собой боль, предпочтительно невропатическую боль, воспалительную боль или другие состояния, связанные с болью, включая аллодинию и/или гипералгезию.
12. Малеатная соль по п.5, для применения при лечении и/или профилактике заболевания, где заболевание представляет собой боль, предпочтительно невропатическую боль, воспалительную боль или другие состояния, связанные с болью, включая аллодинию и/или гипералгезию.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15382436.2 | 2015-09-02 | ||
| EP15382436 | 2015-09-02 | ||
| PCT/EP2016/070604 WO2017037166A1 (en) | 2015-09-02 | 2016-09-01 | 1-(4-(2-((1-(3,4-difluorophenyl)-1h-pyrazol-3-yl)methoxy)ethyl) piperazin-1-yl)ethanone salts |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2018111429A true RU2018111429A (ru) | 2019-10-03 |
| RU2018111429A3 RU2018111429A3 (ru) | 2020-02-04 |
| RU2727974C2 RU2727974C2 (ru) | 2020-07-28 |
Family
ID=54106287
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018111429A RU2727974C2 (ru) | 2015-09-02 | 2016-09-01 | Соли 1-(4-(2-((1-(3,4-дифторфенил)-1н-пиразол-3-ил)метокси)этил)пиперазин-1-ил)этанона |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10640468B2 (ru) |
| EP (1) | EP3344620B1 (ru) |
| JP (1) | JP6893916B2 (ru) |
| KR (1) | KR20180048923A (ru) |
| CN (1) | CN108026078A (ru) |
| AR (1) | AR105888A1 (ru) |
| AU (1) | AU2016315396B2 (ru) |
| CA (1) | CA2997359A1 (ru) |
| CO (1) | CO2018002429A2 (ru) |
| EC (1) | ECSP18015275A (ru) |
| IL (1) | IL257671A (ru) |
| MA (1) | MA43157A (ru) |
| MX (1) | MX390681B (ru) |
| RU (1) | RU2727974C2 (ru) |
| TW (1) | TWI752916B (ru) |
| UA (1) | UA124301C2 (ru) |
| WO (1) | WO2017037166A1 (ru) |
| ZA (1) | ZA201801544B (ru) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3336085A1 (en) | 2016-12-15 | 2018-06-20 | Laboratorios del Dr. Esteve S.A. | Process and intermediate for the preparation of 1-(4-(2-((1-(3,4-difluorophenyl)-1h-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)ethanone |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10259406A1 (de) * | 2002-12-19 | 2004-07-01 | Cognis Deutschland Gmbh & Co. Kg | Milde Detergensgemische |
| DK1781618T3 (da) * | 2004-08-27 | 2012-10-29 | Esteve Labor Dr | Sigma-receptorinhibitorer |
| CA2636797A1 (en) * | 2006-01-19 | 2007-08-23 | Ambrx, Inc. | Non-natural amino acid polypeptides having modulated immunogenicity |
| DK2503993T3 (en) * | 2009-11-25 | 2016-08-22 | Esteve Labor Dr | Hydrochloridsalt af 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]-morpholin |
| EP2395003A1 (en) * | 2010-05-27 | 2011-12-14 | Laboratorios Del. Dr. Esteve, S.A. | Pyrazole compounds as sigma receptor inhibitors |
| MA41177A (fr) * | 2014-12-15 | 2017-10-24 | Esteve Labor Dr | Utilisation de ligands des récepteurs sigma dans l'arthrose |
-
2016
- 2016-09-01 AR ARP160102670A patent/AR105888A1/es unknown
- 2016-09-01 MA MA043157A patent/MA43157A/fr unknown
- 2016-09-01 TW TW105128276A patent/TWI752916B/zh not_active IP Right Cessation
- 2016-09-01 AU AU2016315396A patent/AU2016315396B2/en not_active Ceased
- 2016-09-01 US US15/757,177 patent/US10640468B2/en not_active Expired - Fee Related
- 2016-09-01 CA CA2997359A patent/CA2997359A1/en not_active Abandoned
- 2016-09-01 CN CN201680051109.5A patent/CN108026078A/zh active Pending
- 2016-09-01 EP EP16758212.1A patent/EP3344620B1/en active Active
- 2016-09-01 UA UAA201803348A patent/UA124301C2/uk unknown
- 2016-09-01 KR KR1020187009126A patent/KR20180048923A/ko not_active Ceased
- 2016-09-01 RU RU2018111429A patent/RU2727974C2/ru active
- 2016-09-01 MX MX2018002435A patent/MX390681B/es unknown
- 2016-09-01 JP JP2018510067A patent/JP6893916B2/ja not_active Expired - Fee Related
- 2016-09-01 WO PCT/EP2016/070604 patent/WO2017037166A1/en not_active Ceased
-
2018
- 2018-02-21 IL IL257671A patent/IL257671A/en unknown
- 2018-02-27 EC ECIEPI201815275A patent/ECSP18015275A/es unknown
- 2018-03-02 CO CONC2018/0002429A patent/CO2018002429A2/es unknown
- 2018-03-06 ZA ZA2018/01544A patent/ZA201801544B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20180048923A (ko) | 2018-05-10 |
| WO2017037166A1 (en) | 2017-03-09 |
| JP2018526365A (ja) | 2018-09-13 |
| RU2727974C2 (ru) | 2020-07-28 |
| EP3344620B1 (en) | 2022-10-26 |
| ZA201801544B (en) | 2019-09-25 |
| AU2016315396A1 (en) | 2018-03-22 |
| ECSP18015275A (es) | 2018-04-30 |
| TWI752916B (zh) | 2022-01-21 |
| CO2018002429A2 (es) | 2018-07-19 |
| AR105888A1 (es) | 2017-11-22 |
| AU2016315396B2 (en) | 2021-05-27 |
| MX2018002435A (es) | 2018-06-15 |
| TW201713647A (zh) | 2017-04-16 |
| CA2997359A1 (en) | 2017-03-09 |
| UA124301C2 (uk) | 2021-08-25 |
| MA43157A (fr) | 2018-09-12 |
| IL257671A (en) | 2018-04-30 |
| MX390681B (es) | 2025-03-21 |
| JP6893916B2 (ja) | 2021-06-23 |
| RU2018111429A3 (ru) | 2020-02-04 |
| EP3344620A1 (en) | 2018-07-11 |
| US10640468B2 (en) | 2020-05-05 |
| CN108026078A (zh) | 2018-05-11 |
| US20180251430A1 (en) | 2018-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2012126105A (ru) | Соли 4-[2-[[5-метил-1-(2-нафталинил)-1н-пиразол-3-ил]окси]этил]морфолина | |
| NZ603532A (en) | Pyrazole compounds as sigma receptor inhibitors | |
| Li et al. | Synthesis and biological evaluation of 1, 3-diaryl pyrazole derivatives as potential antibacterial and anti-inflammatory agents | |
| AU2014228344B2 (en) | HDAC inhibitors | |
| EP2262784B1 (en) | Inhibitors of the chemokine receptor cxcr3 | |
| JP2017528506A5 (ru) | ||
| AR067118A1 (es) | Sales de amina del acido{4,6-bis(dimetilamino)-2(4-(4-(trifluorometil)benzamido)bencil)pirimidin-5-il}acetico, composiciones farmaceuticas que las contienen, procesos de preparacion y usos para el tratamiento de procesos alergicos, dermatitis atopica o trastornos inflamatorios. | |
| CL2014000659A1 (es) | Compuestos derivados de 2-(1,2,3-triazol-2-il)benzamida y 3-(1,2,3-triazol-2-il)picolinamida, antagonistas del receptor de orexina; composicion farmaceutica; y su uso para la prevencion o el tratamiento de una enfermedad seleccionada del grupo que consiste en trastornos de ansiedad, adiccion, animicos y del apetito. | |
| CA2581175A1 (en) | Piperidinylamino-thieno[2,3-d] pyrimidine compounds | |
| Revesz et al. | Novel CCR1 antagonists with oral activity in the mouse collagen induced arthritis | |
| MA51999A (fr) | Nouvelle formulation pharmaceutique comprenant des antagonistes doubles des récepteurs nk-1/nk-3 | |
| EA201890695A1 (ru) | Новые пиразолилзамещенные гетероарилы и их применение в качестве лекарственных средств | |
| JP5719852B2 (ja) | ７−クロロ−キノリン−４−アミン化合物、ならびにアミロイド斑の形成を含み、及び／又はａｐｐの代謝機能障害が生じる疾患の予防又は治療のためのそれらの使用 | |
| JP2016540771A5 (ru) | ||
| CN101443312B (zh) | 4-[(3-氟苯氧基)苯基甲基]哌啶甲磺酸盐：用途、合成方法以及药物组合物 | |
| CA3005236C (en) | Heterocyclic compounds for the inhibition and treatment of sphingosine-1-phosphate mediated diseases | |
| RU2018111429A (ru) | Соли 1-(4-(2-((1-(3,4-дифторфенил)-1н-пиразол-3-ил)метокси)этил)пиперазин-1-ил)этанона | |
| NZ595797A (en) | 2,5-disubstituted arylsulfonamide ccr3 antagonists | |
| JP2018526365A5 (ru) | ||
| Kang et al. | Further optimization of novel pyrrole 3-carboxamides for targeting serotonin 5-HT2A, 5-HT2C, and the serotonin transporter as a potential antidepressant | |
| JP2016535757A5 (ru) | ||
| EP3807397A4 (en) | ISOLATION OF MICROBIAL CELL LINES FOR THE PRODUCTION OF ORGANIC ACIDS | |
| IL273751B1 (en) | Salts of (R)-9-(5,2-difluorophenethyl)-4-ethyl-2-methyl-1-oxa-9,4-diazaspiro[5.5]undecan-3-one | |
| CN109476584A (zh) | N-(2-(取代-萘-1-基)乙基)取代酰胺类化合物、其制备及其用途 | |
| SHAFIQ et al. | Synthesis, structural elucidation and antimicrobial evaluation of 2-{4-(T-AMINO)-2-(BUT-2-YN-1-YL)}-1, 3 benzothiazole derivatives |